AI-generated summary
The authors report a randomized, double-blind, placebo-controlled trial of 94 head and neck cancer patients receiving chemoradiation, comparing low-level laser therapy with placebo to prevent oral mucositis. They report that the laser group had lower morbidity and that the therapy was more cost-effective than placebo up to a threshold of at least US$ 5000 per mucositis case prevented, from a Brazilian public health care perspective.
- Participants
- 94
- Who or what was studied
- Patients with head and neck squamous cell carcinoma of the nasopharynx, oropharynx, and hypopharynx receiving concurrent chemoradiation
- Wavelengths
- 660 nm
- Limits stated in the abstract
- The abstract does not describe the cost-effectiveness analysis in detail, and the cost estimates are specific to Brazil's public health care system.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
The full abstract is not shown here because it is protected by the publisher’s copyright. Read it on linkinghub.elsevier.com.
Record from PubMed, a service of the National Library of Medicine.
Light parameters mentioned
Found in the title and abstract by pattern. They may be incomplete, so check the paper before comparing studies.
- Wavelength
- 660 nm
- Energy density (fluence)
- 4J/cm2
- Power
- 100 mW
How to read a trial: what to check before relying on this kind of research.
Terms in this paper: Low-level laser therapy, Laser, Oral mucositis, Placebo-controlled, GRADE. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.